DOUGLAS GROSSMAN portrait
  • Adjunct Professor, Oncological Sciences
  • Professor, Dermatology

Research Keywords

  • Melanoma
  • Moles
  • p16 Tumor Suppressor
  • Survivin
  • Metastasis
  • Oxidative Stress
  • Chemoprevention

Presentations

  • Faculty Speaker, Stiefel Laboratories, Palo Alto, CA; “Melanoma: clinical biology, diagnosis, and new ideas on chemoprevention”. , Presented, 2010.
  • Florida State University, Tallahassee, FL; "Total body photography and molecular testing to guide biopsy decisions for atypical pigmented lesions". , , 2021.
  • University of Arizona, Tuscon, AZ; "Molecular Prognostic Tests for Melanoma Treatment Decision Making". , , 2021.
  • Stanford Dept. of Dermatology, Palo Alto, CA; "Update on gene expression profiling for melanoma". , , 2021.
  • Practical Dermatology for Primary Care Conference, Salt Lake City, UT, "Melanocytic Nevi and Other Characteristically Multifocal Growths". , , 2017.
  • University of California Irvine Cancer Center, Irvine, CA; "Personalized melanoma chemoprevention". , , 2011.
  • Oregon Health Sciences University, Portland, OR; “Adventures in melanoma research”. , , 2011.
  • Practical Dermatology for Primary Care Course, Salt Lake City, UT; "Dermatology Resources for the Primary Care Provider: Mole Mapping". , , 2010.
  • Eugene Van Scott lectureship, Section of Dermatology, University of Chicago, Chicago, IL; “Role of Survivin in melanoma development and progression”. , , 2009.
  • Visiting Professor, Dept. of Dermatology, Yale Univ. School of Medicine, New Haven, CT; “Early melanoma detection – what’s the best approach?” and “Role of Survivin in melanoma development and progression”. , , 2006.
  • Visiting Professor, Cardinal Bernardin Cancer Center, Loyola Univ., Chicago, IL; “Role of the apoptosis inhibitor Survivin in melanoma development”. , , 2006.
  • Visiting Professor, Dept. of Dermatology and Skin Disease Research Center, Univ. of Alabama, Birmingham, AL; “The apoptosis inhibitor Survivin in melanoma development”. , , 2005.
  • Visiting Professor, Dept. of Dermatology and Skin Disease Research Center, Case Western Reserve Univ., Cleveland, OH; “Regulation of apoptosis in melanocytic cells”. , , 2003.
  • PanAmerican Society of Pigment Cell Research (PASPCR), Vancouver, Canada; plenary talk: "Targeting oxidative stress for melanoma chemoprevention". , , 2010.
  • Missouri Dermatological Society, Kansas City, MO; “Strategies for early melanoma detection” and “From bench to beach: towards a novel paradigm for melanoma chemoprevention”. , , 2009.
  • Al Weiner memorial lecturer, Noah Worcester Dermatologic Society, Lake Las Vegas, NV; “Strategies for early melanoma detection” and “From bench to beach: towards a novel paradigm for melanoma chemoprevention”. , , 2009.
  • Society for Investigative Dermatology, St. Louis, MO; Irvin Blank Resident/Fellow Forum; "Melanocyte apoptosis and potential apoptosis-based therapies for melanoma". , , 2005.
  • Society for Investigative Dermatology, general plenary session, Chicago, IL, "Targeting of the apoptosis inhibitor Survivin prevent tumor formation in amouse melanoma model". , , 2000.
  • Melanoma Prevention Working Group symposium (virtual); "Update on Prognostic Gene Expression Profile (GEP)testing in melanoma: Next steps?". , , 2020.
  • Winter Skin 2020, Park City, UT; "Controversies in early-stage melanoma". , , 2020.
  • Georgetown Skin Cancer Symposium (virtual); "Molecular Prognostic Tests for Melanoma Treatment Decision Making". , , 2020.
  • Melanoma Prevention Working Group meeting at Society for Melanoma Research: "Aspirin as a novel UV protectant and melanoma prevention agent". , , 2019.
  • Melanoma and Cutaneous Oncology Primer, Inova Cancer Center, Fairfax, VA; "Gene expression profile testing in melanoma". , , 2019.
  • Osher Lifelong Learning Series, Salt Lake City, UT; "Melanoma in Utah: how we Diagnose, Treat, and Try to Prevent". , , 2019.
  • American Academy of Dermatology, New York, NY; "Total body photography in high risk patients". , , 2019.
  • American Academy of Dermatology, New York, NY; "Update on molecular diagnostic and prognostic tests for melanoma". , , 2019.
  • 22nd Annual Melanoma and Cutaneous Malignancies Symposium, St. Joseph Hospital, Orange, CA; "Controversies in early-stage melanoma". , , 2019.
  • American Academy of Dermatology, Chicago, IL; "New molecular diagnostic and prognostic tests for melanoma". , , 2018.
  • American Academy of Dermatology, Chicago, IL; "Total body photography in high risk patients". , , 2018.
  • Winter Skin Seminar, Park City, UT; "Management of nevi in high risk patients". , , 2017.
  • Pacific Dermatologic Association, Deer Valley, UT: Melanoma Symposium; "Management of patients with nevi". , , 2015.
  • American Academy of Dermatology, San Francisco, CA; "Moderately dysplastic nevi with positive margins (usually) can be observed". , , 2015.
  • American Academy of Dermatology, Denver, CO; "What's new in melanoma chemoprevention?". , , 2014.
  • Society for Investigative Dermatology, Edinburgh, Scotland; Pigmentation & Melanoma Mini-symposium; "Survivin promotes melanoma metastasis through upregulation of α5 integrin". , , 2013.
  • International Melanoma Congress, Tampa, FL; "What's new in melanoma chemoprevention?". , , 2011.
  • Southwest Oncology Group Melanoma prevention working group, Tampa, FL; "A phase II trial of N-acetylcysteine for protection of nevi against UV-induced oxidative stress". , , 2011.
  • Society for Investigative Dermatology, Atlanta, GA; Pigmentation & Melanoma Mini-symposium; "The p16 tumor suppressor regulates oxidative stress". , , 2010.
  • Southwest Oncology Group Melanoma prevention working group, Chicago, IL; "Towards a novel paradigm for melanoma chemoprevention". , , 2009.
  • Society for Investigative Dermatology, Montreal, Canada; Pigmentation & Melanoma Mini-symposium; "Survivin promotes melanocyte migration through upregulation of α5 integrin". , , 2009.
  • Pacific Dermatologic Association, San Francisco, CA; Melanoma Symposium; "Strategies for early melanoma detection". , , 2008.
  • International Investigative Dermatology, Kyoto, Japan; Clinical Research & Therapeutics Mini-symposium; “Use of NAC to protect nevi against UV-induced oxidative stress/damage: towards a novel paradigm for melanoma chemoprevention”. , , 2008.
  • Dept. of Oncological Sciences / HCI Retreat, Deer Valley, UT; “From the bench to the beach: a novel paradigm for melanoma chemoprevention”. , , 2007.
  • CCSG Clinical Cancer Lecture Series, Huntsman Cancer Institute; “Clinical biology of malignant melanoma”. , , 2007.
  • Intermountain Dermatology Society, Sun Valley, ID; "Strategies for early melanoma detection". , , 2007.
  • HCI Cancer Center Retreat, Wells Fargo Center, Salt Lake City, UT; Translational Science Symposium; “Melanoma chemoprevention: a collaborative translational project”. , , 2006.
  • Society for Investigative Dermatology, Philadelphia, PA; Pigmentation & Melanoma Mini-symposium; “Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist”. , , 2006.
  • Society for Investigative Dermatology, St. Louis, MO; Pigmentation & Melanoma Mini-symposium; “Survivin expression in melanocytes confers apoptosis protection and enhances UVB-induced melanoma formation in mice”. , , 2005.
  • Society for Investigative Dermatology, Providence, RI; Carcinogenesis Mini-symposium; “Stage-specific regulation of skin tumor development by apoptosis: survivin enhances mutagenesis yet suppresses clonal expansion”. , , 2004.
  • Huntsman Cancer Institute Retreat, Snowbird, UT; "Survivin and p53 in multi-step skin carcinogenesis". , , 2004.
  • Society for Investigative Dermatology, Miami, FL; Carcinogenesis Mini-symposium; “Survivin targeting triggers rapid translocation of mitochondrial apoptosis-inducing factor in melanoma cells”. , , 2003.
  • Society for Investigative Dermatology, Los Angeles, CA; Carcinogenesis Mini-symposium; "Survivin expression in mouse skin influences multiple steps in experimental carcinogenesis". , , 2002.
  • Young Investigators Symposium, Eccles Institute of Human Genetics, University of Utah; "The apoptosis inhibitor Survivin in human melanoma". , , 2001.
  • Society for Investigative Dermatology Resident Retreat, Airlie Center, Warrenton, VA; "Obtaining a faculty position to pursue a career as an investigative dermatologist". , , 2001.
  • Melanoma Conference, MD Anderson Cancer Center, Houston, TX; "The novel apoptosis inhibitor Survivin in melanoma and non-melanoma skin cancer". , , 2000.
  • American Academy of Dermatology, San Francisco, CA; Resident Symp; "Activated protein C resistance in patients with venous stasis leg ulcers". , , 1997.
  • Federation of American Societies of Experimental Biology, Anaheim, CA, "Vβ analysis of mutant and chimeric staphylococcal enterotoxins". , , 1992.
  • Texas Immunology Conference, San Antonio, TX, "Dissociation of the stimulatory activities of staphylococcal enterotoxins". , , 1990.
  • Melanoma research talk and lab tours for American Heritage School (American Fork, UT). , , 2013.
  • Faculty Speaker, Melanoma Research Alliance, Salt Lake City, UT; "Personalized melanoma chemoprevention". , , 2012.
  • Faculty Speaker, University of Utah Health Care, Melanoma Patient Support Meeting, Deer Valley, UT; "Mole mapping". , , 2012.
  • Faculty Speaker, The McGillis School, Salt Lake City, UT; “The skin and skin cancer”. , , 2012.
  • Faculty Speaker, Huntsman Cancer Institute/Intermountain Healthcare, Salt Lake City, UT; Melanoma Donor and Patient symposium. , , 2007.

Languages

  • English, Fluent.

Publications

  • Cassidy PB, Leachman SA, Grossman D (date unknown). N-acetylcysteine for Reduction of Oxidative Stress-Damage and Prevention of Melanoma. Springer. Accepted, .
  • Grossman D, Leffell DJ (date unknown). Squamous cell carcinoma. McGraw-Hill. Accepted, .
  • Cassidy PB, Grossman D, Leachman SA (date unknown). Melanoma Prevention. (pp. 30-42). Future Medicine Ltd. Accepted, .
  • Grossman D, Leffell DJ (date unknown). Squamous cell carcinoma. McGraw-Hill. Accepted, .
  • Grossman D, Leffell DJ (date unknown). Squamous cell carcinoma. McGraw-Hill. Accepted, .
  • Grossman D, Leffell DJ (date unknown). The clinical biology and molecular basis of squamous cell carcinoma. Oxford University Press. Accepted, .
  • Shah A, Hyngstrom J, Florell SR, Grossman D (date unknown). Use of the Pigmented Lesion Assay to rapidly screen a patient with numerous clinically atypical pigmented lesions. (pp. 1048-1050). Vol. 5. Accepted, .
  • Grossman D (date unknown). Imatinib mesylate for melanoma: will a new target be revealed?. (pp. xi-xiii). Vol. 123. Accepted, .
  • Grossman D, Duffy KL, Bowen GM (date unknown). Surgical margins for melanoma in situ. (pp. 1068-9; author reply 1069-71). Vol. 67. Accepted, .
  • Grossman D, Bowen GM (date unknown). Commentary on impact of National Comprehensive Cancer Network Guidelines on Case Selection and Outcomes for Sentinel Lymph Node Biopsy in Thin Melanoma. (pp. 502-503). Accepted, .
  • Kim CC, Swetter S, Curiel-Lewandrowski, Grichnik J, Grossman D, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Nelson KC, Veledar E, Venna SS, Chen S (date unknown). Complete excision of atypical/dysplastic nevi: Addressing the gap in clinical practice recommendations and need for more data to guide management. Pigmented Lesion Subcommittee consensus statement. (pp. 212-218). Vol. 151. Accepted, .
  • Cotter MA, Florell SR, Leachman SA, Grossman D (date unknown). Reply to responses to "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". (pp. 1583-1584). Vol. 128. Accepted, .
  • Grossman D (date unknown). Failure to compare dermoscopy findings of pigmented lesions on your patient: Comment on "Dermoscopy of patients with multiple nevi". (pp. 50). Vol. 147. Accepted, .
  • Grossman D, Duvic M (date unknown). Reply to response to "Idiopathic CD4 T-lymphocytopenia in a patient with mycosis fungoides". (pp. 1064). Vol. 32. Accepted, .
  • Leachman SA, Smalley KSM, Grossman D, Bowen GM, Messina JL, Berwick M, Glass LF, Swetter SM, Sondak V (date unknown). Joint melanoma meetings in Tampa enhance communication and collaboration. (pp. 129-131). Vol. 7. Accepted, .
  • Varedi A, Wu YP, Klein SZ, Leachman SA, Grossman D (date unknown). Mineral sunscreens not recommended by Consumer Reports: Suggestions to improve the review process. Vol. 80, 832-833. Accepted, .
  • Grossman D, Kim CC, Hartman RI, Berry E, Nelson KC, Okwundu N, Curiel-Lewandrowski C, Leachman SA, Swetter SM (date unknown). Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Vol. 6, MMT32. Accepted, .
  • Grossman D, Duvic M (date unknown). Cutaneous T-cell lymphoma after blood transfusion. (pp. 1483). Vol. 342. Accepted, .
  • Teerlink CC, Huff C, Stevens J, Yu Y, Holmen SL, Silvis MR, Trombetti K, Zhao H, Grossman D, Farnham JM, Wen J, Facelli JC, Thomas A, Babst M, Florell SR, Meyer L, Zone JJ, Leachman S, Cannon-Albright LA (date unknown). A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma. Vol. 110, 1380-1385. Accepted, .
  • Kim CC, Berry EG, Marchetti MA, Swetter SM, Lim G, Grossman D, Curiel-Lewandrowski C, Chu EY, Ming ME, Zhu K, Brahmbhatt M, Balakrishnan V, Davis MJ, Wolner Z, Fleming N, Ferris LK, Nguyen J, Trofymenko O, Liu Y, Chen SC, Pigmented Lesion Subcommittee, Melanoma Prevention Working Group. (date unknown). Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. Vol. 154, 1401-1408. Accepted, .
  • Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW (date unknown). Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Vol. 27, 545-557. Accepted, .
  • King AJ, Gehl RW, Grossman D, Jensen JD (date unknown). Skin self-examinations and visual identification of atypical nevi: comparing individual and crowdsourcing approaches. Vol. 37, 979-84. Accepted, .
  • Goodson AG, Cotter MA, Cassidy P, Wade M, Florell SR, Liu T, Boucher KM, Grossman D (date unknown). Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Vol. 15, 7434-40. Accepted, .
  • Florell SR, Meyer LJ, Boucher KM, Hart M, Cannon-Albright LA, Harris RM, Grossman D, Samlowski WE, Zone JJ, Brinton JP, Leachman SA (date unknown). Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation. Vol. 125, 1310-2. Accepted, .
  • Florell SR, Schmidt SJ, Porter-Gill P, Albertine KH, Murphy KJ, McKinney CB, Boucher KM, Grossman D, Biddle DL, Clayton F, Layfield LJ, Leachman SA (date unknown). Novel application of a fibrin cell block method to evaluate melanocytic cell populations. Vol. 16, 662-9. Accepted, .
  • McGovern TW, Grossman D, Fitzgerald D, Glusac EJ, Leffell D (date unknown). Status of residual tumor in patients with squamous cell carcinoma referred for Mohs micrographic surgery. (pp. 1557-9). Vol. 135. Accepted, .
  • Grossman D, McNiff JM, Li F, Altieri DC (date unknown). Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. Vol. 113, 1076-81. Accepted, .
  • Grossman D, Lamphear JG, Mollick JA, Betley MJ, Rich RR (date unknown). Dual roles for class II major histocompatibility complex molecules in staphylococcal enterotoxin-induced cytokine production and in vivo toxicity. Vol. 60, 5190-6. Accepted, .
  • Grossman D, Cook RG, Sparrow JT, Mollick JA, Rich RR (date unknown). Dissociation of the stimulatory activities of staphylococcal enterotoxins for T cells and monocytes. Vol. 172, 1831-41. Accepted, .
  • Luo X, Zhou Y, Smart T, Grossman D, Sanchez B (date unknown). Electrical Characterization of Basal Cell Carcinoma Using a Handheld Electrical Impedance Dermography Device. Vol. 2, 100075. Accepted, .
  • McNeal AS, Belote RL, Zeng H, Urquijo M, Barker K, Torres R, Curtin M, Shain AH, Andtbacka RH, Holmen S, Lum DH, McCalmont TH, VanBrocklin MW, Grossman D, Wei ML, Lang UE, Judson-Torres RL (date unknown). BRAFV600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB. Vol. 10. Accepted, .
  • O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC (date unknown). Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Vol. 97, 13103-7. Accepted, .
  • Grossman D, Van M, Mollick JA, Highlander SK, Rich RR (date unknown). Mutation of the disulfide loop in staphylococcal enterotoxin A. Consequences for T cell recognition. Vol. 147, 3274-81. Accepted, .
  • Okwundu N, Rahman H, Liu T, Florell SR, Boucher KM, Grossman D (date unknown). A randomized double-blind placebo-controlled trial of oral aspirin for protection of melanocytic nevi against UV-induced DNA damage. Accepted, .
  • Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM, Grossman D (date unknown). Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Vol. 25, 6968-74. Accepted, .
  • Hawryluk EB, Moustafa D, Bartenstein D, Brahmbhatt M, Cordoro K, Gardner L, Gauthier A, Grossman D, Gupta D, Hunt RD, Jen M, Kao PC, Kruse LL, Lawley LP, London WB, Mansour D, O'Haver JA, Phung T, Pope E, Price HN, Rogers T, Shah SD, Wolner Z, Huang J, Marghoob AA (date unknown). A retrospective multicenter study of fatal pediatric melanoma. Vol. 83, 1274-1281. Accepted, .
  • Nagelhout ES, Parsons BG, Haaland B, Tercyak KP, Zaugg K, Zhu A, Harding G, Yancey J, Jensen JD, Grossman D, Wetter DW, Wu YP (date unknown). Differences in reported sun protection practices, skin cancer knowledge, and perceived risk for skin cancer between rural and urban high school students. Vol. 30, 1251-1258. Accepted, .
  • Malvehy J, Hauschild A, Curiel-Lewandrowski C, Mohr P, Hofmann-Wellenhof R, Motley R, Berking C, Grossman D, Paoli J, Loquai C, Olah J, Reinhold U, Wenger H, Dirschka T, Davis S, Henderson C, Rabinovitz H, Welzel J, Schadendorf D, Birgersson U (date unknown). Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. Vol. 171, 1099-107. Accepted, .
  • Goodson AG, Florell SR, Boucher KM, Grossman D (date unknown). A decade of melanomas: identification of factors associated with delayed detection in an academic group practice. Vol. 37, 1620-30. Accepted, .
  • McKenzie JA, Liu T, Goodson AG, Grossman D (date unknown). Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Vol. 70, 7927-37. Accepted, .
  • Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Chellapandian D, Dávila Saldaña BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM, submitted on behalf of the Primary Immune Deficiency Treatment Consortium. (date unknown). Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. Vol. 39, 653-667. Accepted, .
  • Kumar D, Rahman H, Tyagi E, Liu T, Li C, Lu R, Lum D, Holmen SL, Maschek JA, Cox JE, VanBrocklin MW, Grossman D (date unknown). Aspirin Suppresses PGE2 and Activates AMP Kinase to Inhibit Melanoma Cell Motility, Pigmentation, and Selective Tumor Growth In Vivo. Vol. 11, 629-642. Accepted, .
  • Wu YP, Parsons BG, Mooney R, Aspinwall LG, Cloyes K, Hay JL, Kohlmann W, Grossman D, Leachman SA (date unknown). Barriers and Facilitators to Melanoma Prevention and Control Behaviors Among At-Risk Children. Vol. 43, 993-1001. Accepted, .
  • Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (date unknown). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Vol. 27, 477-484. Accepted, .
  • Fuller SR, Bowen GM, Tanner B, Florell SR, Grossman D (date unknown). Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma. Vol. 33, 1198-206; discussion 1205-6. Accepted, .
  • Cotter MA, Florell SR, Leachman SA, Grossman D (date unknown). Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. (pp. 2469-71). Vol. 127. Accepted, .
  • Cotter MA, Thomas J, Cassidy P, Robinette K, Jenkins N, Florell SR, Leachman S, Samlowski WE, Grossman D (date unknown). N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Vol. 13, 5952-8. Accepted, .
  • Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM, Leachman SA, Grossman D (date unknown). Activation of dual apoptotic pathways in human melanocytes and protection by survivin. Vol. 126, 2247-56. Accepted, .
  • Liu J, Dai Q, Chen J, Durrant D, Freeman A, Liu T, Grossman D, Lee RM (date unknown). Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Vol. 1, 892-902. Accepted, .
  • Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC (date unknown). Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. Vol. 108, 991-9. Accepted, .
  • Parsons BG, Nagelhout ES, Wankier AP, Hu N, Lensink R, Zhu A, Nottingham K, Grossman D, Jensen JD, Wu YP (date unknown). Reactivity to UV Radiation Exposure Monitoring Using Personal Exposure Devices for Skin Cancer Prevention: Longitudinal Observational Study. Vol. 9, e29694. Accepted, .
  • Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RHI, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (date unknown). Intratumoral ipilimumab and interleukin-2 produce high rates of abscopal responses with low toxicity in patients with advanced melanoma. Vol. 7, 64390-99. Accepted, .
  • Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (date unknown). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Vol. 7, 64390-64399. Accepted, .
  • Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (date unknown). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. Vol. 156, 1004-1011. Accepted, .
  • Li C, Liu T, Liu B, Hernandez R, Facelli JC, Grossman D (date unknown). A novel CDKN2A variant (p16L117P ) in a patient with familial and multiple primary melanomas. Vol. 32, 734-738. Accepted, .
  • John KK, Jensen JD, King AJ, Ratcliff CL, Grossman D (date unknown). Do Pattern-Focused Visuals Improve Skin Self-Examination Performance? Explicating the Visual Skill Acquisition Model. Vol. 22, 732-742. Accepted, .
  • McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman D (date unknown). Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Vol. 34, 2137-44. Accepted, .
  • Florell SR, Thomas J, Grossman D (date unknown). Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation. Vol. 34, 667-74. Accepted, .
  • Yan H, Brouha B, Liu T, Raj D, Biddle D, Lee R, Grossman D (date unknown). Proteolytic cleavage of Livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase. Vol. 43, 189-200. Accepted, .
  • Diedrich MJ, Warters RL, Grossman D (date unknown). Amifostine aminothiols and protection of keratinocyte apoptosis and DNA damage. Vol. 119, 707-8. Accepted, .
  • Grossman D, McNiff JM, Li F, Altieri DC (date unknown). Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Vol. 79, 1121-6. Accepted, .
  • Grossman D, Heald PW, Wang C, Rinder HM (date unknown). Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Vol. 37, 409-13. Accepted, .
  • Casey MJ, Modzelewska K, Anderson D, Goodman J, Boer EF, Jimenez L, Grossman D, Stewart RA (date unknown). A zebrafish brain tumor transplantation method for the long-term study of tumor cell behavior and drug response. Vol. 123, e55712. Accepted, .
  • Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC (date unknown). Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. (pp. 452-3). Vol. 341. Accepted, .
  • Tyagi E, Liu B, Li C, Liu T, Rutter J, Grossman D (date unknown). Loss of p16INK4A stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway. Vol. 8, 55848-55862. Accepted, .
  • Nelson KC, Grossman D, Kim CC, Chen SC, Curiel-Lewandrowski CN, Grichnik JM, Kirkwood JM, Leachman SA, Marghoob AA, Swetter SM, Venna SS, Ming ME (date unknown). Management strategies of academic pigmented lesion clinic directors in the United States. Vol. 79, 367-369. Accepted, .
  • Grossman D, Farnham JM, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright LA (date unknown). Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011). Vol. 79, 238-244. Accepted, .
  • Wu YP, Aspinwall LG, Nagelhout E, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Cassidy P, Leachman SA (date unknown). Development of an Educational Program Integrating Concepts of Genetic Risk and Preventive Strategies for Children with a Family History of Melanoma. Vol. 33, 774-781. Accepted, .
  • Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Leachman SA (date unknown). Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. Vol. 128, 2122-5. Accepted, .
  • He Y, Liu J, Grossman D, Durrant D, Sweatman T, Lothstein L, Epand RF, Epand RM, Lee RM (date unknown). Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. Vol. 101, 1210-21. Accepted, .
  • Grossman D, Lewis DE, Ballas ZK, Duvic M (date unknown). Idiopathic CD4+ T lymphocytopenia in a patient with mycosis fungoides. Vol. 31, 275-6. Accepted, .
  • Harris TO, Grossman D, Kappler JW, Marrack P, Rich RR, Betley MJ (date unknown). Lack of complete correlation between emetic and T-cell-stimulatory activities of staphylococcal enterotoxins. Vol. 61, 3175-83. Accepted, .
  • Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich RR (date unknown). A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. Vol. 92, 710-9. Accepted, .
  • Sarris AH, Esgleyes-Ribot T, Crow M, Broxmeyer HE, Karasavvas N, Pugh W, Grossman D, Deisseroth A, Duvic M (date unknown). Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma?. Vol. 86, 651-8. Accepted, .
  • Truong A, Strazzulla L, March J, Boucher KM, Nelson KC, Kim CC, Grossman D (date unknown). Reduction in nevus biopsies in patients monitored by total body photography. Vol. 75, 135-143.e5. Accepted, .
  • Duffy K, Grossman D (date unknown). The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. Vol. 67, 1.e1-16; quiz 17-8. Accepted, .
  • Duffy K, Grossman D (date unknown). The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. Vol. 67, 19.e1-12; quiz 31-2. Accepted, .
  • Goodson AG, Florell SR, Hyde M, Bowen GM, Grossman D (date unknown). Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma. Vol. 36, 1087-98. Accepted, .
  • LaBarbera DV, Modzelewska K, Glazar AI, Gray PD, Kaur M, Liu T, Grossman D, Harper MK, Kuwada SK, Moghal N, Ireland CM (date unknown). The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Vol. 20, 425-36. Accepted, .
  • Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U (date unknown). The dark side of immunotherapy. Vol. 9, 1041. Accepted, .
  • Li C, Liu T, Tavtigian SV, Boucher K, Kohlmann W, Cannon-Albright L, Grossman D (date unknown). Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants. Vol. 30, 247-251. Accepted, .
  • Parsons BG, Hay JL, Aspinwall LG, Zaugg K, Zhu A, Mooney RH, Klein SZ, Grossman D, Leachman SA, Wu YP (date unknown). Understanding Skin Screening Practices Among Children at Elevated Risk for Melanoma to Inform Interventions for Melanoma Prevention and Control. Vol. 35, 509-514. Accepted, .
  • Hyde MA, Grossman D, Wu YP, Buys S, Gren LH, Hashibe M (date unknown). Vitamin D, melanoma risk, and tumor thickness in PLCO cancer screening trial patients. Vol. 33, 35-41. Accepted, .
  • March J, Hand M, Grossman D (date unknown). Practical application of new technologies for melanoma diagnosis: Part I. Noninvasive approaches. Vol. 72, 929-41; quiz 941-2. Accepted, .
  • Goodman JR, Grossman D (date unknown). Aspirin and other NSAIDs as chemoprevention agents in melanoma. Vol. 7, 557-64. Accepted, .
  • Florell SR: Smoller BR, Boucher KM, Grossman D, Harris RM, Bowen GM, Leachman SA, (date unknown). Sampling of melanocytic nevi for research purposes: A prospective study to determine effect on diagnosis. Vol. 59, 814-821. Accepted, .
  • Liu J, Epand R, Durrant D, Grossman D, Epand R, Lee R (date unknown). Regulation of tBid-induced apoptosis by mitochondrial phospholipid scramblase 3. Vol. 47, 4529. Accepted, .
  • Thomas J, Liu T, Cotter MA, Florell SR, Robinette K, Hanks AN, Grossman D (date unknown). Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Vol. 67, 5172-8. Accepted, .
  • Bowen AR, Hanks AN, Murphy KJ, Florell SR, Grossman D (date unknown). Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Vol. 26, 177-81. Accepted, .
  • Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, Zone JJ, Noyes RD, Bowen GM, Leachman SA (date unknown). Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. Vol. 21, 2179-86. Accepted, .
  • Wu YP, Parsons BG, Aspinwall LG, Hay JL, Boucher KM, Caputo H, Mooney R, Grossman D, Leachman SA (date unknown). Parent and child perspectives on perceived barriers to child sun protection and their association with sun protection strategies among children of melanoma survivors. Vol. 36, 317-323. Accepted, .
  • Goodson AG, Varedi A, Hull C, Grossman D (date unknown). A safe and efficient model for ultraviolet radiation-induced herpes simplex labialis. Vol. 31, 170-2. Accepted, .
  • Goodson AG, Grossman D (date unknown). Strategies for early melanoma detection: Approaches to the patient with nevi. Vol. 60, 719-35; quiz 736-8. Accepted, .
  • Liu J, Epand RF, Durrant D, Grossman D, Chi NW, Epand RM, Lee RM (date unknown). Role of phospholipid scramblase 3 in the regulation of tumor necrosis factor-alpha-induced apoptosis. Vol. 47, 4518-29. Accepted, .
  • John KK, Jensen JD, King AJ, Pokharel M, Grossman D (date unknown). Emerging applications of eye-tracking technology in dermatology. Accepted, .
  • Haynes D, Strunck JL, Said J, Tam I, Varedi A, Topham CA, Olamiju B, Wei BM, Erickson MK, Wang LL, Tan A, Stoner R, Hartman RI, Lilly E, Grossman D, Curtis JA, Westerdahl JS, Leventhal JS, Choi JN, Chu EY, Ming ME, Stein JA, Liebman TN, Berry E, Greiling TM (date unknown). Association between halo nevi and melanoma in adults: A multicenter retrospective case series. Vol. 84, 1164-1166. Accepted, .
  • Truong A, Hyngstrom JR, Andtbacka RHI, Noyes RD, Wright M, Snyder J, Winters A, Sause WT, Grossmann KF, Khong HT, Bowen GM, Hitchcock YJ, Grossman D, Bowles TL (date unknown). Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status. Vol. 30, 173-178. Accepted, .
  • Jensen JD, Pokharel M, King AJ, John KK, Wu YP, Grossman D (date unknown). Obstacles to skin self-examination: are frontier adults inclined abstainers?. Vol. 25, 470-479. Accepted, .
  • Strunck JL, Smart TC, Boucher KM, Secrest AM, Grossman D (date unknown). Improved melanoma outcomes and survival in patients monitored by total body photography: A natural experiment. Vol. 47, 342-347. Accepted, .
  • Parsons BG, Gren LH, Simonsen SE, Harding G, Grossman D, Wu YP (date unknown). Opportunities for Skin Cancer Prevention Education among Individuals Attending a Community Skin Cancer Screening in a High-Risk Catchment Area. Vol. 43, 212-219. Accepted, .
  • Grossman D, Bowen GM (date unknown). Commentary on Impact of National Comprehensive Cancer Network Guidelines on Case Selection and Outcomes for Sentinel Lymph Node Biopsy in Thin Melanoma. Vol. 44, 502-503. Accepted, .
  • Jenkins NC, Jung J, Liu T, Wilde M, Holmen SL, Grossman D (date unknown). Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions. Vol. 133, 1043-51. Accepted, .
  • Grossman D, Bowen GM (date unknown). Commentary: transecting melanomas: does it matter?. Vol. 39, 616-7. Accepted, .
  • Goodson AG, Florell SR, Boucher KM, Grossman D (date unknown). Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. Vol. 62, 591-6. Accepted, .
  • Strunck JL, Florell SR, Grossman D (date unknown). Capillary hemangioma associated with dermal atrophy masquerading as a deep fungal infection.LID - 13030/qt4109m7ds [pii]. Vol. 24. Accepted, .
  • Cassidy PB, Fain HD, Cassidy JP Jr, Tran SM, Moos PJ, Boucher KM, Gerads R, Florell SR, Grossman D, Leachman SA (date unknown). Selenium for the prevention of cutaneous melanoma. Vol. 5, 725-49. Accepted, .
  • Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM (date unknown). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. Accepted, .
  • Wu YP, Nagelhout E, Aspinwall LG, Boucher KM, Parsons BG, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Leachman SA (date unknown). A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Vol. 101, 452-459. Accepted, .
  • Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK (date unknown). Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Vol. 4, 13-37. Accepted, .
  • Soltani-Arabshahi R, Sweeney C, Jones B, Florell SR, Hu N, Grossman D (date unknown). Predictive value of biopsy specimens suspicious for melanoma: support for 6-mm criterion in the ABCD rule. Vol. 72, 412-8. Accepted, .
  • Nagelhout ES, Lensink R, Zhu A, Parsons BG, Haaland B, Hashibe M, Grossman D, VanDerslice J, Gren LH, Jensen JD, Wu YP (date unknown). Higher Ultraviolet Radiation Exposure Among Rural-Dwelling Versus Urban-Dwelling Adults and Children: Implications for Skin Cancer Prevention. Vol. 46, 147-155. Accepted, .
  • Wu YP, Kohlmann W, Curtin K, Yu Z, Hanson HA, Hashibe M, Parsons BG, Wong J, Schiffman JD, Grossman D, Leachman SA (date unknown). Melanoma risk assessment based on relatives' age at diagnosis. Vol. 29, 193-199. Accepted, .
  • Andtbacka RH, Donaldson MR, Bowles TL, Bowen GM, Grossmann K, Khong H, Grossman D, Anker C, Florell SR, Bowen A, Duffy KL, Leachman SA, Noyes RD (date unknown). Sentinel lymph node biopsy for melanoma in pregnant women. Vol. 20, 689-96. Accepted, .
  • Raj D, Brash DE, Grossman D (date unknown). Keratinocyte apoptosis in epidermal development and disease. Vol. 126, 243-57. Accepted, .
  • Alexander A, Harris RM, Grossman D, Bruggers CS, Leachman SA (date unknown). Vulvar melanoma: diffuse melanosis and metastasis to the placenta. Vol. 50, 293-8. Accepted, .
  • Allen SM, Florell SR, Hanks AN, Alexander A, Diedrich MJ, Altieri DC, Grossman D (date unknown). Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Vol. 63, 567-72. Accepted, .
  • Grossman D, Rapini RP, Osborne B, Duvic M (date unknown). Emergence of leprosy in a patient with mycosis fungoides. Vol. 30, 313-5. Accepted, .
  • Mollick JA, McMasters RL, Grossman D, Rich RR (date unknown). Localization of a site on bacterial superantigens that determines T cell receptor beta chain specificity. Vol. 177, 283-93. Accepted, .
  • Jenkins NC, Liu T, Cassidy P, Leachman SA, Boucher KM, Goodson AG, Samadashwily G, Grossman D (date unknown). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Vol. 30, 265-74. Accepted, .
  • Grossman D, Kim PJ, Schechner JS, Altieri DC (date unknown). Inhibition of melanoma tumor growth in vivo by survivin targeting. Vol. 98, 635-40. Accepted, .
  • Liu T, Brouha B, Grossman D (date unknown). Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Vol. 23, 39-48. Accepted, .
  • Varedi A, Rahman H, Kumar D, Catrow JL, Cox JE, Liu T, Florell SR, Boucher KM, Okwundu N, Burnett WJ, VanBrocklin MW, Grossman D (date unknown). ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma. Vol. 13. Accepted, .
  • Flint ND, Bishop MD, Smart TC, Strunck JL, Boucher KM, Grossman D, Secrest AM (date unknown). Low accuracy of self-reported family history of melanoma in high-risk patients. Vol. 20, 41-48. Accepted, .
  • Rahman H, Kumar D, Liu T, Okwundu N, Lum D, Florell SR, Burd CE, Boucher KM, VanBrocklin MW, Grossman D (date unknown). Aspirin Protects Melanocytes and Keratinocytes against UVB-Induced DNA Damage In Vivo. Vol. 141, 132-141.e3. Accepted, .
  • Varedi A, Gardner LJ, Kim CC, Chu EY, Ming ME, Leachman SA, Curiel-Lewandrowski C, Swetter SM, Grossman D (date unknown). Use of new molecular tests for melanoma by pigmented-lesion experts. (pp. 245-247). Vol. 82. Accepted, .
  • Wu YP, Boucher K, Hu N, Hay J, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Grossman D, Mooney K, Leachman SA, Tercyak KP (date unknown). A pilot study of a telehealth family-focused melanoma preventive intervention for children with a family history of melanoma. Vol. 29, 148-155. Accepted, .
  • Gardner LJ, Strunck JL, Wu YP, Grossman D (date unknown). Current controversies in early-stage melanoma: Questions on incidence, screening, and histologic regression. Vol. 80, 1-12. Accepted, .
  • Klapperich ME, Bowen GM, Grossman D (date unknown). Current controversies in early-stage melanoma: Questions on management and surveillance. Vol. 80, 15-25. Accepted, .
  • Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB (date unknown). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Vol. 125, 18-44. Accepted, .
  • Cassidy PB, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman D (date unknown). A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Vol. 10, 36-44. Accepted, .
  • King AJ, Carcioppolo N, Grossman D, John KK, Jensen JD (date unknown). A randomised test of printed educational materials about melanoma detection: Varying skin self-examination technique and visual image dose. Vol. 74, 732-42. Accepted, .
  • Jenkins NC, Grossman D (date unknown). Role of melanin in melanocyte dysregulation of reactive oxygen species. Vol. 2013, 908797. Accepted, .
  • Raj D, Liu T, Samadashwily G, Li F, Grossman D (date unknown). Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Vol. 29, 194-201. Accepted, .
  • Zhang W, Hanks AN, Boucher K, Florell SR, Allen SM, Alexander A, Brash DE, Grossman D (date unknown). UVB-induced apoptosis drives clonal expansion during skin tumor development. Vol. 26, 249-57. Accepted, .
  • Florell SR, Bowen AR, Hanks AN, Murphy KJ, Grossman D (date unknown). Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. Vol. 32, 45-9. Accepted, .
  • Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA (date unknown). Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Vol. 65, 18-27. Accepted, .
  • Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D (date unknown). Apoptosis regulators and responses in human melanocytic and keratinocytic cells. Vol. 120, 48-55. Accepted, .
  • Grossman D, Altieri DC (date unknown). Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Vol. 20, 3-11. Accepted, .
  • Varedi A, Bishop MD, Boucher KM, Kim CC, Grossman D (date unknown). Powering a prospective melanoma chemoprevention trial in high-risk cohorts. (pp. e232-e234). Vol. 58. Accepted, .
  • Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D (date unknown). Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. (pp. 835-8). Vol. 71. Accepted, .
  • Duvic M, Grossman D (date unknown). More on acyclovir for chickenpox. (pp. 59). Vol. 331. Accepted, .
  • Chang MS, Leachman SA, Berry EG, Curiel-Lewandrowski C, Geller AC, Grossman D, Kim CC, Stein JA, Swetter SM, Hartman RI (date unknown). Changes in melanoma care practices during the COVID-19 pandemic: a multi-institutional cross-sectional survey. Vol. 27. Accepted, .
  • Grossman D, Sweeney C, Doherty JA (date unknown). The Rapid Rise in Cutaneous Melanoma Diagnoses. (pp. e54). Vol. 384. Accepted, .
  • Grossman D, Florell SR, Duffy KL, Bowen GM (date unknown). Histologic criteria for assessing surgical margins in melanoma in situ. (pp. e133-e134). Vol. 82. Accepted, .
  • Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (date unknown). Impact of the COVID-19 pandemic on exercise habits among cancer patients. Accepted, .
  • Grossman D, Leffell DJ (date unknown). The molecular basis of nonmelanoma skin cancer: new understanding. Vol. 133, 1263-70. Accepted, .
  • March J, Hand M, Truong A, Grossman D (date unknown). Practical application of new technologies for melanoma diagnosis: Part II. Molecular approaches. (pp. 943-58; quiz 959-60). Vol. 72. Accepted, .
  • Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Melanoma Research Foundation. (date unknown). The State of Melanoma: Emergent Challenges and Opportunities. (pp. 2678-2697). Vol. 27. Accepted, .
  • Brash DE, Zhang W, Grossman D, Takeuchi S (date unknown). Colonization of adjacent stem cell compartments by mutant keratinocytes. (pp. 97-102). Vol. 15. Accepted, .
  • Pho L, Grossman D, Leachman SA (date unknown). Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. (pp. 173-9). Vol. 18. Accepted, .
  • Kim CC, Swetter SM, Curiel-Lewandrowski C, Grichnik JM, Grossman D, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Nelson KC, Veledar E, Venna SS, Chen SC (date unknown). Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. (pp. 212-8). Vol. 151. Accepted, .
  • McKenzie JA, Grossman D (date unknown). Role of the apoptotic and mitotic regulator survivin in melanoma. Vol. 32, 397-404. Accepted, .
  • Hand M, Chien A, Grossman D (date unknown). Screening and non-invasive evaluative devices for melanoma detection: a comparison of commercially available devices and dermoscopic evaluation. (pp. 005). Vol. 2. Accepted, .